EPISODE · May 19, 2026
AVACTA GROUP PLC - Preliminary Results for the year ended December 31, 2025
from Investor Meet Podcast - AI · host Investor Meet Company
Today's podcast explores Avacta Group PLC's fiscal 2025 preliminary results, focusing on their innovative cancer therapy approach using a two amino acid cap. This method aims to transform targeted cancer treatments by bypassing traditional chemotherapy's harmful effects. Avacta's precision platform targets the FAP enzyme found in 90% of solid tumors, allowing for significant drug concentration directly within the tumor while minimizing damage to healthy tissues. Clinical data from their Gen 1 program, AVA 6000, shows promising results without systemic toxicity, leading to an increased lifetime maximum dose limit for patients. The company is now aggressively pursuing US-based Gen 2 trials, positioned for potential transformative advances in the coming 9 to 12 months.
Embed this episode
Ready to play
AVACTA GROUP PLC - Preliminary Results for the year ended December 31, 2025
No transcript for this episode yet
Similar Episodes
No similar episodes found.